Number of people in your group:
1 to 5
6 to 10
11 to 15
16 to 20
Developer of therapies designed to provide treatment of retinal diseases. The company's KSI 301 helps to restore vision and stop progression of underlying disease, enabling healthcare providers to cure their patients.